C-OAXVgenetic medicines, non-viral delivery, senescent cell removal
Editor’s Choice. Hand-picked by the Eternal Search editors as worth your attention — a curatorial call shown alongside, not instead of, the computed score.
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Enable non-viral delivery of DNA and RNA payloads for genetic medicines targeting health, longevity, and age-related conditions.
Proteo-lipid vehicle delivery technology for DNA and RNA payloads.
Entos Pharmaceuticals announced a $198.5 million government partnership to accelerate biomanufacturing of Fusogenix PLV next-generation therapeutics.
Advance therapies for age-related diseases using Oisín's genetic medicine approach.
Preclinical development of genetic medicine platform and investigational therapy candidates.
Seed financing brought total funding to $9.5 million to support preclinical development of the platform and an investigational therapy.
Develop an investigational therapy for kidney-related age-related disease indications.
Investigational therapy supported by Oisín's preclinical genetic medicine platform.
Seed financing was stated to support preclinical development of an investigational therapy for kidney-related disease context.
Target fat cells as part of Oisín's age-related condition pipeline.
Genetic medicine approach using non-viral DNA/RNA delivery technology.
Listed in supplied site analysis as part of Oisín's pipeline targets.
Target frailty as a driver or manifestation of age-related conditions.
Genetic medicine approach using non-viral DNA/RNA delivery technology.
Listed in supplied site analysis as part of Oisín's pipeline targets.
Enable redosable genetic medicines using non-viral delivery for DNA and RNA payloads, with extrahepatic biodistribution and repeat dosing.
Non-viral Fusogenix Proteo-Lipid Vehicle delivery of DNA and RNA payloads.
Core delivery mechanism was published in Cell in 2024; seed financing was stated to support preclinical development of the platform.
Publication title states safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles.
Target biology of aging, including klotho biology, extracellular-matrix remodeling, mitochondrial function, cellular reprogramming, and senescent cell clearance.
Genetic medicine research programs using non-viral Fusogenix PLV delivery for aging-biology payloads.
Listed in the company pipeline in the supplied site analysis; related healthspan-extension publication is listed in filtered publications.
Develop a genetic medicine program for muscle building.
Oisín genetic medicine approach using non-viral Fusogenix PLV delivery.
Listed in the company pipeline in the supplied site analysis.
Target senescent cells as a driver of age-related conditions.
Genetic medicine and senolytic approach using non-viral delivery technology.
Listed in supplied site analysis as part of Oisín's pipeline targets.
Develop a genetic medicine program for targeted fat removal.
Oisín genetic medicine approach using non-viral Fusogenix PLV delivery.
Listed in the company pipeline in the supplied site analysis.
Enable targeted production of a therapeutic protein within a target cell.
Systems and methods for producing a therapeutic protein within a selected target cell, described in an Oisín Biotechnologies patent family.
Google Patents record for WO2014160661A3 lists the application as ceased.